Oral administration of the CaN inhibitor FK506 (Astellas Pharma, 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan; trade names: Tacrolimus, Prograf, Advagraf, Protopic7) has been proven to increase RGC survival and optic nerve preservation in a glaucoma animal model [16], and also to reduce RGC death in an optic nerve crush model [18,19]. The gene discussed is NUP214; the disease is glaucoma.